ACLX Live signaler | Maksimer profitt med Getagraph.com

SELG 116223 min ago

@ $63.29

Utstedt: 14 feb 2024 @ 15:30

Avkastning: -16.74%

Forrige signal: feb 12 - 19:39

Forrige signal: Kjøp

Avkastning: -0.81 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases...

Stats
Dagens volum	387 208
Gjennomsnittsvolum	457 951
Markedsverdi	2.78B
EPS	$0 ( 2024-04-03 )
Neste inntjeningsdato	( $-0.510 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-35.84
ATR14	$0.0520 (0.10%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Heery Christopher	Sell	10 000	Stock Option (right to buy)
2024-05-01	Heery Christopher	Buy	18 168	Common Stock
2024-05-01	Heery Christopher	Sell	7 087	Common Stock
2024-05-01	Heery Christopher	Sell	8 168	Stock Option (right to buy)
2024-05-01	Heery Christopher	Sell	10 481	Common Stock

INSIDER POWER
-46.88
Last 100 transactions
Buy: 1 137 648 \| Sell: 3 745 923

Volum Korrelasjon

Lang: 0.01 (neutral)

Kort: 0.04 (neutral)

Signal:(46.964) Neutral

Arcellx, Inc. Korrelasjon

10 Mest positive korrelasjoner
RMRM	0.953
MOTNU	0.932
LIAN	0.911
NYMX	0.911
AGYS	0.909
SDIG	0.909
PSCH	0.908
GLMD	0.908
PSCC	0.906
ICON	0.906

10 Mest negative korrelasjoner
ATHN	-0.935
NXTC	-0.932
PTRA	-0.932
IOAC	-0.932
LITE	-0.93
GTLB	-0.928
CWBR	-0.924
AXDX	-0.921
TSLA	-0.92
LGHL	-0.917

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Arcellx, Inc. Korrelasjon - Valuta/Råvare

0.50
( neutral )

0.55
( weak )

0.68
( moderate )

0.50
( neutral )

0.06
( neutral )

Arcellx, Inc. Økonomi

Annual	2023
Omsetning:	$110.32M
Bruttogevinst:	$108.28M (98.15 %)
EPS:	$-1.470

FY	2023
Omsetning:	$110.32M
Bruttogevinst:	$108.28M (98.15 %)
EPS:	$-1.470

FY	2022
Omsetning:	$0
Bruttogevinst:	$-2.22M (0.00 %)
EPS:	$-4.22

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-6.02

Financial Reports:

No articles found.

Arcellx, Inc.

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.